论文部分内容阅读
目的:探讨CD44、血管内皮生长因子(VEGF)在中度恶性NHL中的表达及其预后意义。方法:采用酶联免疫法检测60例中度恶性NHL患者化疗前CD44、VEGF含量,观察他们与疗效和复发率的关系。结果:患者治疗前的CD44、VEGF浓度少于中位浓度的治疗有效率明显高于对照组,复发率明显低于对照组,差异均有统计学意义(P<0.05)。结论:CD44、VEGF水平可以用于中度恶性NHL患者疗效和预后的初步判断,为估计标准方案疗效不佳或容易复发患者设计或选择新的临床试验,以期取得更好的效果。
Objective: To investigate the expression of CD44 and vascular endothelial growth factor (VEGF) in moderately malignant NHL and its prognostic significance. Methods: The levels of CD44 and VEGF in 60 patients with moderate malignant NHL before chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA), and their relationship with the efficacy and recurrence rate were observed. Results: The therapeutic effective rate of patients with CD44 and VEGF less than the median before treatment was significantly higher than that of the control group, and the recurrence rate was significantly lower than that of the control group (P <0.05). Conclusion: The levels of CD44 and VEGF can be used to evaluate the efficacy and prognosis of patients with moderate malignant NHL. We designed or selected new clinical trials to evaluate the efficacy of the standard regimen in patients with poor prognosis or relapse, so as to achieve better results.